Geron Osake

Geron P/FCF

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Geron (GERN) 16.8.2026 päivämäärällä on −9,48. Edellisenä vuonna P/FCF (Hinta-vapaa-kassavirta-suhde) oli −4,80 — muutos 97,41 % (matalampi).

P/FCF

−9,48

YoY

97,41%

Viimeksi päivitetty:

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Geron on 2026 −9,48 . P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Geron oli 2025 −4,80 . Se laskee 97,41% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Geron Osakeanalyysi

Mitä Geron tekee? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Geron osakkeesta

Yhtiön Geron P/FCF (Hinta-vapaa-kassavirta-suhde) on −9,48 vuonna 2026.

P/FCF (Hinta-vapaa-kassavirta-suhde) yhtiöstä Geron muuttui arvosta −4,80 arvoon −9,48, mikä edustaa 97,41 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää P/FCF (Hinta-vapaa-kassavirta-suhde) Geron:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Hinta-vapaa-kassavirta-suhde mittaa, kuinka paljon sijoittajat maksavat jokaista vapaan kassavirran yksikköä kohti. Matalampi suhde voi viitata parempaan arvoon.

P/FCF = Markkina-arvo / Vapaa kassavirta

Arvioidakseen P/FCF (Hinta-vapaa-kassavirta-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja P/FCF (Hinta-vapaa-kassavirta-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata P/FCF (Hinta-vapaa-kassavirta-suhde):n Geron alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Geron

Kaikki tunnusluvut — Geron